Investing further into molecular glue degraders, Genentech has signed a multi-year collaboration with Orionis Biosciences to develop small molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration. The deal, worth up to over US$2 B, will leverage Orionis’ molecular glue degrader platform, known as Allo-GlueTM, for the discovery of small molecule monovalent glues. Interest in these therapeutic modalities has been ramping up in recent months, with large ticket deals also announced by companies such as Merck & Co. and Bristol Myers Squibb.